| Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression RM Awad, Y De Vlaeminck, J Maebe, C Goyvaerts, K Breckpot Frontiers in immunology 9, 408722, 2018 | 154 | 2018 |
| Theranostics in immuno-oncology using nanobody derivatives Q Lecocq, Y De Vlaeminck, H Hanssens, M D'Huyvetter, G Raes, ... Theranostics 9 (25), 7772, 2019 | 96 | 2019 |
| TUBA1A mutations: From isolated lissencephaly to familial polymicrogyria AC Jansen, A Oostra, B Desprechins, Y De Vlaeminck, H Verhelst, ... Neurology 76 (11), 988-992, 2011 | 79 | 2011 |
| Cancer-associated myeloid regulatory cells Y De Vlaeminck, A González-Rascón, C Goyvaerts, K Breckpot Frontiers in immunology 7, 186873, 2016 | 78 | 2016 |
| Noninvasive imaging of the immune checkpoint LAG-3 using nanobodies, from development to pre-clinical use Q Lecocq, K Zeven, Y De Vlaeminck, S Martens, S Massa, C Goyvaerts, ... Biomolecules 9 (10), 548, 2019 | 48 | 2019 |
| Single-domain antibody nuclear imaging allows noninvasive quantification of LAG-3 expression by tumor-infiltrating leukocytes and predicts response of immune checkpoint blockade Q Lecocq, RM Awad, Y De Vlaeminck, W De Mey, T Ertveldt, C Goyvaerts, ... Journal of Nuclear Medicine 62 (11), 1638-1644, 2021 | 33 | 2021 |
| Perforin and granzyme B expressed by murine myeloid-derived suppressor cells: a study on their role in outgrowth of cancer cells I Dufait, J Pardo, D Escors, Y De Vlaeminck, H Jiang, M Keyaerts, ... Cancers 11 (6), 808, 2019 | 27 | 2019 |
| Targeting neuropilin-1 with nanobodies reduces colorectal carcinoma development Y De Vlaeminck, S Bonelli, RM Awad, M Dewilde, S Rizzolio, Q Lecocq, ... Cancers 12 (12), 3582, 2020 | 26 | 2020 |
| Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages Y De Vlaeminck, Q Lecocq, P Giron, C Heirman, X Geeraerts, E Bolli, ... Journal of controlled release 299, 107-120, 2019 | 19 | 2019 |
| Emerging applications of nanobodies in cancer therapy RM Awad, F Meeus, H Ceuppens, T Ertveldt, H Hanssens, Q Lecocq, ... International review of cell and molecular biology 369, 143-199, 2022 | 14 | 2022 |
| Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade RM Awad, Q Lecocq, K Zeven, T Ertveldt, L De Beck, H Ceuppens, ... Molecular Therapy-Methods & Clinical Development 22, 172-182, 2021 | 13 | 2021 |
| Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery C Goyvaerts, Y De Vlaeminck, D Escors, S Lienenklaus, M Keyaerts, ... Gene Therapy 24 (6), 370-375, 2017 | 13 | 2017 |
| TNF-α-secreting lung tumor-infiltrated monocytes play a pivotal role during anti-PD-L1 immunotherapy K De Ridder, H Locy, E Piccioni, MI Zuazo, RM Awad, S Verhulst, ... Frontiers in Immunology 13, 811867, 2022 | 11 | 2022 |
| MSH2 knock-down shows CTG repeat stability and concomitant upstream demethylation at the DMPK locus in myotonic dystrophy type 1 human embryonic stem … S Franck, L Barbé, S Ardui, Y De Vlaeminck, J Allemeersch, D Dziedzicka, ... Human Molecular Genetics 29 (21), 3566-3577, 2020 | 7 | 2020 |
| Targeted radionuclide therapy with low and high-dose lutetium-177–labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model T Ertveldt, L De Beck, K De Ridder, H Locy, W De Mey, C Goyvaerts, ... Molecular Cancer Therapeutics 21 (7), 1136-1148, 2022 | 6 | 2022 |
| Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer Q Lecocq, P Debie, J Puttemans, RM Awad, L De Beck, T Ertveldt, ... EJNMMI research 11 (1), 115, 2021 | 6 | 2021 |
| Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor … T Ertveldt, A Krasniqi, H Ceuppens, J Puttemans, Y Dekempeneer, ... Journal of Nuclear Medicine 64 (5), 751-758, 2023 | 5 | 2023 |
| In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4+ T cells RM Awad, Y De Vlaeminck, F Meeus, T Ertveldt, K Zeven, H Ceuppens, ... Scientific reports 13 (1), 18995, 2023 | 2 | 2023 |
| Inhibiting histone and DNA methylation improves cancer vaccination in an experimental model of melanoma L De Beck, RM Awad, V Basso, N Casares, K De Ridder, Y De Vlaeminck, ... Frontiers in Immunology 13, 799636, 2022 | 2 | 2022 |
| Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine T Ertveldt, S Meulewaeter, Y De Vlaeminck, O Olarte, K Broos, ... Theranostics 13 (15), 5483, 2023 | 1 | 2023 |
